Geode Capital Management LLC Reduces Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Geode Capital Management LLC trimmed its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,994,350 shares of the biopharmaceutical company’s stock after selling 5,585 shares during the period. Geode Capital Management LLC owned approximately 2.28% of Dynavax Technologies worth $38,246,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Norges Bank purchased a new stake in Dynavax Technologies during the 4th quarter worth about $7,762,000. WINTON GROUP Ltd grew its position in shares of Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock valued at $5,450,000 after purchasing an additional 329,579 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Dynavax Technologies by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after buying an additional 232,690 shares in the last quarter. Barclays PLC boosted its stake in Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after buying an additional 175,118 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies during the 4th quarter valued at about $990,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Down 0.3 %

Shares of Dynavax Technologies stock opened at $11.41 on Wednesday. The company’s fifty day simple moving average is $13.13 and its two-hundred day simple moving average is $12.58. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.42 billion, a P/E ratio of 63.39 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DVAX shares. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. Finally, HC Wainwright reissued a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.